Meeting Announcement: Aprea Therapeutics to Present at the 7th International Mutant p53 Workshop in Melbourne, Australia

By | | No Comments

Dr. Mikael von Euler will present data from Aprea Therapeutics’ Phase Ib study in high-grade serous ovarian cancer at the 7th International Mutant p53 Workshop in Melbourne, Australia. This oral presentation is scheduled for 11:35 AM on Friday October 28, 2016 as part of Session 11: Mutant p53 therapies.

Presentation title: PISARRO: A EUTROC phase 1b study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC)

Aprea Therapeutics Announces First Patients Enrolled in Phase II Clinical Study of APR-246 for the Treatment of High-Grade Serous Ovarian Cancer

By | | No Comments
October 10, 2016—Aprea Therapeutics AB, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, announced today that it enrolled the first patients in the Phase II part of the ongoing clinical study of APR-246 for the treatment of high-grade serous ovarian cancer.
Read More

Aprea Therapeutics Announces Efficacy and Safety Data in High-Grade Serous Ovarian Cancer Patients Treated with APR-246 in Presentation at 2016 European Society for Medical Oncology (ESMO) Annual Meeting

By | | No Comments
October 10, 2016—Aprea Therapeutics AB, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II clinical study in collaboration with the European Network for Translational Research in Ovarian Cancer (EUTROC). The Phase Ib portion of the PiSARRO clinical study investigated the safety and efficacy of APR-246 in combination with carboplatin and pegylated liposomal doxorubicin (PLD) in patients with relapsed high-grade serous ovarian cancer.
Read More

Aprea AB announces efficacy and safety data in high-grade serous ovarian cancer patients treated with investigational APR-246 presented at 2016 ASCO Annual Meeting

By | | No Comments
June 6, 2016—Aprea AB, a privately held, clinical-stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial in collaboration with the European Network for Translational Research in Ovarian Cancer (EUTROC).
Read More